SCHEMBL7260255

SCHEMBL7260255

O=C(O)C=C1CN(C(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
KDM4E B2RXH2 2/20 0.51
MAPT P10636 2/20 0.51
KMT2A Q03164 4/20 0.49
MEN1 O00255 2/20 0.49
MAOB P27338 1/20 0.47
HPGD P15428 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
CACNA2D1 P54289 2/20 0.45
CACNA1B Q00975 2/20 0.45
CACNB1 Q02641 2/20 0.45
CACNA1C Q13936 2/20 0.45
CACNA1H O95180 1/20 0.45
OPRD1 P41143 1/20 0.44
MGLL Q99685 1/20 0.44
ATM Q13315 1/20 0.44
CYP2D6 P10635 2/20 0.43
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM5 P08912 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8495166 0.86 KMT2A (0.54) ALDH1A1KDM4EMAPTKMT2AMEN1
SCHEMBL15415069 0.82 CYP2D6 (0.48) ALDH1A1KDM4EMAPTKMT2AMEN1
SCHEMBL5280062 0.80 ALDH1A1 (0.54) ALDH1A1KDM4EMAPTKMT2AMEN1
SCHEMBL5280064 0.80 ALDH1A1 (0.54) ALDH1A1KDM4EMAPTKMT2AMEN1
SCHEMBL17726461 0.78 KMT2A (0.50) ALDH1A1KDM4EMAPTKMT2AMEN1
SCHEMBL71975 0.78 CTDSP1 (0.49) MAPTKMT2AMEN1NPSR1CACNA2D1
SCHEMBL9430599 0.77 MAPT (0.40) ALDH1A1KDM4EMAPTKMT2AMEN1
SCHEMBL9430603 0.77 OPRD1 (0.38) ALDH1A1KDM4EKMT2AMEN1CACNA2D1
SCHEMBL4826291 0.74 OPRM1 (0.47) ALDH1A1KDM4EMAPTKMT2AMEN1
SCHEMBL3131844 0.74 OPRM1 (0.44) ALDH1A1KDM4EMAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110520422-B Novel pyridonecarboxylic acid derivative or salt thereof 涌永制药株式会社 2023-09-05 CN disclosed
US-8129366-B2 VLA-4 inhibitory drug DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-06 US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed
WO-2003013526-A1 ANTICOAGULANT COMPOUNDS MERCK & CO. INC. (US) 2003-02-20 WO disclosed
EP-0630374-B1 IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES MERCK SHARP & DOHME (GB) 2001-09-05 EP disclosed
US-5567726-A SELECTIVE AGONISTS OF 5-HYDROXYTRYPTAMINE-LIKE RECEPTORS; USEFUL IN TREATMENT OF MIGRAINE AND ASSOCIATED DISORDERS MERCK, SHARP & DOHME LTD. (GB) 1996-10-22 US disclosed
US-5510362-A VASOCONSTRUCTION MERCK, SHARP AND DOHME LIMITED (GB) 1996-04-23 US disclosed
EP-0630374-A1 IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES MERCK SHARP & DOHME LTD. (GB) 1994-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233901-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 ALDH1A1 525/4885KDM4E 1607/4885MAPT 4795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.